Inhibamet 12.5/500 mg, 30 tablets

Trade Name:

Inhibamet 12.5/500 mg

Composition

Each tablet contains:

Alogliptin 12.5 mg

Metformin hydrochloride 500 mg

Properties

Inhibamet is a combination of two hypoglycemic agents with complementary and different mechanisms of action designed to improve glycemic control in patients with type 2 diabetes mellitus (T2DM): alogliptin, an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), and metformin, a member of the biguanide class .

Indications

Type 2 diabetes mellitus in adults aged 18 years and older to improve glycemic control in addition to diet and exercise.

Dosage and administration

The drug is taken orally.

Assign 1 tab. 2 times / day simultaneously with food intake in order to reduce unwanted reactions from the gastrointestinal tract. The tablets should be swallowed whole, without chewing, with water.

The dose of the drug is selected individually.

Contraindications

Hypersensitivity to alogliptin or metformin or any of the excipients.type 1 diabetes;

diabetic ketoacidosis, diabetic precoma, coma;

moderate or severe renal failure (creatinine clearance less than 60 ml / min);

Storage

Store at a temperature not exceeding 30°C.

Package:

The cardboard box contains 1, 2 or 3 blisters of 10 tablets, paper leaflet.